Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

This is a single-arm, multicenter, prospective, open-label phase II clinical trial of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy treating oligometastatic nasopharyngeal carcinoma, the main purpose of which is to evaluate the efficacy of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy regimen in treating oligometastatic nasopharyngeal carcinoma.

Trial Details

NCT ID
NCT05290194
Phase
PHASE2
Sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • SBRT radiotherapy + Conventionally fractionated radiotherapy
  • PD-1 inhibitor
  • Capecitabine
Locations (sample)
  • Zhuhai, Guangdong, China|22.27694,113.56778

Key Eligibility Criteria

  • The patient was histologically or cytologically diagnosed with nasopharyngeal carcinoma;
  • The patient was newly diagnosed with metastatic nasopharyngeal carcinoma (AJCC eighth edition), and after 4-6 cycles of gemcitabine plus cisplatin …
  • Except for the primary tumor and cervical lymph node metastasis, less than 5 distant organ metastases, and were suitable for SBRT radiotherapy;
  • ECOG PS score 0-2 points;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →